A recent study indicates that people who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle programs.
Findings released in a major medical journal shows that while obese people frequently drop about a fifth of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments need to be aware of the danger of quick rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about a year and a half.
Comparing Approaches
The study, which reviewed 37 of studies involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Researchers point out that individuals who shed pounds through diet and exercise generally see a slower weight regain—around 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Nutrition scientists believe the way of the injections explains the heightened regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, due to the likelihood of relapse, the therapy is often ongoing.
This perspective is echoed by drug manufacturers, who state that the results "underscore the long-term nature of excess weight," comparing it to managing diseases like diabetes.
User Accounts
People who have come off the jabs report a powerful resurgence of cravings.
"It was like a trigger that goes on and you're instantly starving," said one woman.
This challenge is exacerbated if patients have not established permanent dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and long-term success likely depends on ongoing behavioural management.
